GTCR commits up to $200m for 2nd Fiorentino-led venture
This article was originally published in Scrip
Executive Summary
The private equity firm GTCR is placing another bet with Ed Fiorentino by investing up to $200 million in the newly formed Crealta Pharmaceuticals, which will acquire assets and companies hand-picked by Fiorentino and his team.